Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue.

Front Oncol · 2022 · PMC9259985 · PMID 35814399

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The analysis was conducted with RWD from 17 observational studies and showed a favorable trend in outcomes and cost effectiveness for the sequence abiraterone acetate-enzalutamide compared to enzalutamide-abiraterone acetate.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.